The field of clinical oncology continues to see drastic advancements with non-invasive techniques, such as liquid biopsy being adopted for diagnosing and monitoring cancers in place of more invasive methods. . However, several limitations still hamper the implementation of liquid biopsy in clinical practice. Join the webinar to learn how liquid biopsies may help with treatment selection and monitoring of cancer treatment outcomes and the current challenges limiting clinical practice adoption….
Cancer Type: Lung
No time to wait: Evolving testing & treatment landscape in early stage lung cancer
Lung cancer has seen tremendous advancements over the past decade with the emergence of targeted therapies directed against mutant onco-proteins and immune checkpoint inhibitors. Join the webinar to hear thoracic multidisciplinary teams of pathologists, surgeons and oncologists from Korea and Thailand share updates in the testing and treatment setting for early stage non-small cell lung cancer….
Value-based care in lung cancer: a case study from Belgium
To enable value-based healthcare, several important steps are needed. In this presentation and Q&A, Ingel Demedts discusses the project “Value-based care in lung cancer: a case study from Belgium”, which aims to investigate if value-based healthcare is feasible in clinical practice for lung cancer patients….
Digital Tools to Drive NGS Clinical Application for the Future
The growing amount of clinical data available for each patient, clinicians need to manage massive genomic information, histological analysis tools, and clinical trials and publications. They must depend on connecting with other clinicians and digital tools to support decision making. Join the webinar to hear from Assoc. Prof. Jason CH Hsieh and Assoc. Prof. Svetlana Cherepanoff on the potential of using digital clinical analysis and communication tools to help make optimal patient decisions….
Connecting Oncology and Pathology in the personalized care of NSCLC patients
Treatment landscape of NSCLC has been evolving dramatically in the past ten years, and biomarker testing is becoming increasingly complex. Join the webinar to hear from Prof Tony Mok and Prof Keith Kerr about the updates on treatment options in NSCLC, the oncology and pathology perspectives on molecular testing challenges and considerations in the clinical decision-making for lung cancer patients….
Clinical Utility of Liquid Biopsy in EGFR testing for Lung Cancer
Several EGFR tyrosine kinase inhibitors are recommended by international guidelines as first-line treatment for patients with EGFR mutations. While tissue biopsy samples continue to be the gold standard, it is not feasible in all patients. Join the webinar to hear from Dr. Noemi Reguart and Dr Kuo Chih-Hsi on how liquid biopsy provides a non-invasive option for patients in order for them to access molecular testing….